Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2018 | Consensus article

European Headache Federation guideline on idiopathic intracranial hypertension

Authors: Jan Hoffmann, Susan P Mollan, Koen Paemeleire, Christian Lampl, Rigmor H Jensen, Alexandra J Sinclair

Published in: The Journal of Headache and Pain | Issue 1/2018

Abstract

Background

Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP no identifiable cause. The aetiology remains largely unknown, however observations made in a number of recent clinical studies are increasing the understanding of the disease and now provide the basis for evidence-based treatment strategies.

Methods

The Embase, CDSR, CENTRAL, DARE and MEDLINE databases were searched up to 1st June 2018. We analyzed randomized controlled trials and systematic reviews that investigate IIH.

Results

Diagnostic uncertainty, headache morbidity and visual loss are among the highest concerns of clinicians and patients in this disease area. Research in this field is infrequent due to the rarity of the disease and the lack of understanding of the underlying pathology.

Conclusions

This European Headache Federation consensus paper provides evidence-based recommendations and practical advice on the investigation and management of IIH.

Available only for authorised users

Mollan SP et al (2016) Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry 87(9):982–992PubMed

Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81(13):1159–1165PubMed

Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211

Markey KA et al (2016) Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. The Lancet Neurology 15(1):78–91PubMed

Hoffmann J, Goadsby PJ (2013) Update on intracranial hypertension and hypotension. Curr Opin Neurol 26(3):240–247PubMed

Almarzouqi SJ, Morgan ML, Lee AG (2015) Idiopathic intracranial hypertension in the Middle East: a growing concern. Saudi J Ophthalmol 29(1):26–31PubMed

Wall M et al (2014) The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 71(6):693–701PubMedCentralPubMed

Giuseffi V et al (1991) Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case control study. Neurology 41(2 Part 1):239PubMed

Mulla Y et al (2015) Headache determines quality of life in idiopathic intracranial hypertension. The Journal of Headache and Pain 16(1):45PubMedCentral

10.

Yri HM et al (2014) The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol 21(12):1458–1464PubMed

11.

Friedman DI et al (2017) Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache: The Journal of Head and Face Pain 57(8):1195–1205

12.

Hoffmann J et al (2014) Volumetric assessment of optic nerve sheath and Hypophysis in idiopathic intracranial hypertension. AJNR Am J Neuroradiol 35(3):513–518PubMedPubMedCentral

13.

Yri H et al (2012) Idiopathic intracranial hypertension is not benign: a long-term outcome study. J Neurol 259(5):886–894PubMed

14.

Wall M (1990) The headache profile of idiopathic intracranial hypertension. Cephalalgia 10(6):331–335PubMed

15.

Bono F et al (2006) Bilateral transverse sinus stenosis predicts IIH without papilledema in patients with migraine. Neurology 67(3):419–423PubMed

16.

Bono F et al (2008) Bilateral transverse sinus stenosis and idiopathic intracranial hypertension without papilledema in chronic tension-type headache. J Neurol 255(6):807–812PubMed

17.

Ducros A, Biousse V (2015) Headache arising from idiopathic changes in CSF pressure. The Lancet Neurology 14(6):655–668PubMed

18.

Yri HM, Jensen RH (2015) Idiopathic intracranial hypertension: clinical nosography and field-testing of the ICHD diagnostic criteria. A case-control study. Cephalalgia 35(7):553–562PubMed

19.

Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24(Suppl 1):9–160

20.

Wall M, White WN 2nd (1998) Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci 39(1):134–142PubMed

21.

Bidot S et al (2015) Asymmetric papilledema in idiopathic intracranial hypertension. J Neuroophthalmol 35(1):31–36PubMedCentralPubMed

22.

Keltner JL et al (2014) Baseline visual field findings in the idiopathic intracranial hypertension treatment trial (IIHTT). Invest Ophthalmol Vis Sci 55(5):3200–3207PubMedCentralPubMed

23.

Lepore FE (1992) Unilateral and highly asymmetric papilledema in pseudotumor cerebri. Neurology 42(3 Pt 1):676–678PubMed

24.

Maxner CE, Freedman MI, Corbett JJ (1987) Asymmetric papilledema and visual loss in pseudotumour cerebri. Can J Neurol Sci 14(4):593–596PubMed

25.

Wall M (2010) Idiopathic intracranial hypertension. Neurol Clin 28(3):593–617PubMedCentralPubMed

26.

Fisayo A et al (2016) Overdiagnosis of idiopathic intracranial hypertension. Neurology 86(4):341–350PubMedCentralPubMed

27.

Digre KB et al (2009) A comparison of idiopathic intracranial hypertension with and without papilledema. Headache 49(2):185–193PubMedCentralPubMed

28.

Wall M et al (2015) Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology 85(9):799–805PubMedCentralPubMed

29.

Pollak L et al (2013) Reevaluation of presentation and course of idiopathic intracranial hypertension – a large cohort comprehensive study. Acta Neurol Scand 127(6):406–412PubMed

30.

Kutzko KE, Brito CF, Wall M (2000) Effect of instructions on conventional automated Perimetry. Invest Ophthalmol Vis Sci 41(7):2006–2013PubMed

31.

Cello KE et al (2016) Factors affecting visual field outcomes in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol 36(1):6–12PubMed

32.

Fard MA et al (2014) Quantification of peripapillary total retinal volume in pseudopapilledema and mild papilledema using spectral-domain optical coherence tomography. Am J Ophthalmol 158(1):136–143PubMed

33.

Kulkarni KM et al (2014) Differentiating mild papilledema and buried optic nerve head drusen using spectral domain optical coherence tomography. Ophthalmology 121(4):959–963PubMed

34.

Kaufhold F et al (2012) Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS One 7(5):e36965PubMedCentralPubMed

35.

Skau M et al (2013) Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension. Graefes Arch Clin Exp Ophthalmol 251(2):567–574PubMed

36.

Aojula A et al (2018) Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmol 17(1):257PubMedPubMedCentral

37.

Rebolleda G, Muñoz-Negrete FJ (2009) Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography. Invest Ophthalmol Vis Sci 50(11):5197–5200PubMed

38.

Schmidt C et al (2012) Structural olfactory nerve changes in patients suffering from idiopathic intracranial hypertension. PLoS One 7(4):e35221PubMedCentralPubMed

39.

Khoo KF, Kunte H (2014) Olfactory dysfunction in patients with idiopathic intracranial hypertension. Neurology 82(2):189PubMed

40.

Kunte H et al (2013) Olfactory dysfunction in patients with idiopathic intracranial hypertension. Neurology 81(4):379–382PubMed

41.

Wall M, George D (1991) Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 114(Pt 1A):155–180PubMed

42.

Mollan SP et al (2014) A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. Pract Neurol 14(6):380–390PubMedCentralPubMed

43.

Mollan SP et al (2018) Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiat 89(10):1088–1100

44.

Kaplan CP, Miner ME, McGregor JM (1997) Pseudotumour cerebri: risk for cognitive impairment? Brain Inj 11(4):293–303PubMed

45.

Sorensen PS, Thomsen AM, Gjerris F (1986) Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurol Scand 73(3):264–268PubMed

46.

Kharkar S et al (2011) Cognitive impairment in patients with Pseudotumor Cerebri syndrome. Behav Neurol 24(2):143–148PubMedCentralPubMed

47.

Yri HM et al (2014) Cognitive function in idiopathic intracranial hypertension: a prospective case–control study. BMJ Open 4(4):e004376PubMedCentralPubMed

48.

Degnan AJ, Levy LM (2011) Narrowing of Meckel's cave and cavernous sinus and enlargement of the optic nerve sheath in Pseudotumor Cerebri. J Comput Assist Tomogr 35(2):308–312PubMed

49.

Hoffmann J et al (2013) Morphometric and volumetric MRI changes in idiopathic intracranial hypertension. Cephalalgia 33(13):1075–1084PubMed

50.

Agid R et al (2006) Idiopathic intracranial hypertension: the validity of cross-sectional neuroimaging signs. Neuroradiology 48(8):521–527PubMed

51.

Degnan AJ, Levy LM (2011) Pseudotumor Cerebri: brief review of clinical syndrome and imaging findings. AJNR Am J Neuroradiol 32(11):1986–1993PubMedPubMedCentral

52.

Jacobson HG, Shapiro JH (1964) Pseudotumor Cerebri. Radiology 82:202–210PubMed

53.

Jacobson DM et al (1990) Computed tomography ventricular size has no predictive value in diagnosing pseudotumor cerebri. Neurology 40(9):1454–1455PubMed

54.

Ahmed RM et al (2011) Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol 32(8):1408–1414PubMedPubMedCentral

55.

Riggeal BD et al (2013) Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 80(3):289–295PubMedCentralPubMed

56.

Biousse V, Bruce BB, Newman NJ (2012) Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 83(5):488–494PubMed

57.

Zouaoui A, Hidden G (1988) Cerebral venous sinuses: anatomical variants or thrombosis? Acta Anat (Basel) 133(4):318–324

58.

Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808

59.

Avery RA et al (2010) Reference range for cerebrospinal fluid opening pressure in children. N Engl J Med 363(9):891–893PubMedCentralPubMed

60.

Torbey MT et al (2004) Utility of CSF pressure monitoring to identify idiopathic intracranial hypertension without papilledema in patients with chronic daily headache. Cephalalgia 24(6):495–502PubMed

61.

Bono F et al (2010) Abnormal pressure waves in headache sufferers with bilateral transverse sinus stenosis. Cephalalgia 30(12):1419–1425PubMed

62.

Toma AK et al (2010) Continuous intracranial pressure monitoring in pseudotumour cerebri: Single centre experience. Br J Neurosurg 24(5):584–588PubMed

63.

Warden KF et al (2011) Short-term continuous intraparenchymal intracranial pressure monitoring in presumed idiopathic intracranial hypertension. J Neuroophthalmol 31(3):202–205PubMed

64.

Whiteley W et al (2006) CSF opening pressure: reference interval and the effect of body mass index. Neurology 67(9):1690–1691PubMed

65.

Mollan SP et al (2009) Idiopathic intracranial hypertension associated with Iron deficiency Anaemia: a lesson for management. Eur Neurol 62(2):105–108PubMed

66.

Kalyvas AV et al (2017) Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. Acta Neurochir 159(1):33–49PubMed

67.

Sinclair AJ et al (2011) Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 31(16):1627–1633PubMed

68.

Abubaker K et al (2011) Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculoperitoneal shunts – case series and literature review. Br J Neurosurg 25(1):94–99PubMed

69.

Banta JT, Farris BK (2000) Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology 107(10):1907–1912PubMed

70.

Uretsky S (2009) Surgical interventions for idiopathic intracranial hypertension. Curr Opin Ophthalmol 20(6):451–455PubMed

71.

Durst CR et al (2016) Prevalence of dural venous sinus stenosis and hypoplasia in a generalized population. Journal of NeuroInterventional Surgery 8(11):1173–1177PubMed

72.

King JO et al (2002) Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology 58(1):26–30PubMed

73.

Teleb MS et al (2013) Idiopathic intracranial hypertension: a systematic analysis of transverse sinus stenting. Interventional Neurology 2(3):132–143PubMed

74.

Liu KC et al (2017) Venous sinus stenting for reduction of intracranial pressure in IIH: a prospective pilot study. J Neurosurg 127(5):1126–1133PubMed

75.

Daniels AB et al (2007) Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 143(4):635–641PubMed

76.

Sinclair A et al (2010) Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 7:341

77.

Subramaniam S, Fletcher WA (2017) Obesity and weight loss in idiopathic intracranial hypertension: a narrative review. J Neuroophthalmol 37(2):197–205PubMed

78.

Mann T et al (2007) Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol 62(3):220–233PubMed

79.

Hutter MM et al (2011) First report from the American College of Surgeons bariatric surgery center network: laparoscopic sleeve Gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 254(3):410–422PubMed

80.

Sjöström L (2013) Review of the key results from the Swedish obese subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 273(3):219–234PubMed

81.

Picot J et al (2009) The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13(41):214

82.

Young MT et al (2015) Use and outcomes of laparoscopic sleeve Gastrectomy vs laparoscopic gastric bypass: analysis of the American College of Surgeons NSQIP. J Am Coll Surg 220(5):880–885PubMed

83.

Manfield JH et al (2017) Bariatric surgery or non-surgical weight loss for idiopathic intracranial hypertension? A systematic review and comparison of meta-analyses. Obes Surg 27(2):513–521PubMed

84.

Ottridge R et al (2017) Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open 7:e017426:1–8PubMedCentralPubMed

85.

Piper RJ et al (2015) Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev (8):CD003434

86.

Wall M et al (2014) Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. Jama 311(16):1641–1651PubMed

87.

Ball AK et al (2011) A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol 258(5):874–881PubMed

88.

Epstein DL, Grant W (1977) Carbonic anhydrase inhibitor side effects: serum chemical analysis. Arch Ophthalmol 95(8):1378–1382PubMed

89.

ten Hove MW et al (2016) Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol 36(1):13–19PubMed

90.

Lee AG et al (2005) The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol 139(5):855–859PubMed

91.

Falardeau J et al (2013) The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol 33(1):9–12. https://doi.org/10.1097/WNO.0b013e3182594001 CrossRefPubMed

92.

Vogh BP, Langham MR (1981) The effect of furosemide and bumetanide on cerebrospinal fluid formation. Brain Res 221(1):171–183PubMed

93.

Melby JM, Miner LC, Reed DJ (1982) Effect of acetazolamide and furosemide on the production and composition of cerebrospinal fluid from the cat choroid plexus. Can J Physiol Pharmacol 60(3):405–409PubMed

94.

Reed DJ (1969) The effect of furosemide on cerebrospinal fluid flow in rabbits. Arch Int Pharmacodyn Ther 178(2):324–330PubMed

95.

McCarthy KD, Reed DJ (1974) The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther 189(1):194–201PubMed

96.

Schoeman JF (1994) Childhood Pseudotumor Cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 9(2):130–134PubMed

97.

Davson H, Segal MB (1970) The effects of some inhibitors and accelerators of sodium transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol 209(1):131–153PubMedCentralPubMed

98.

Murphy VA, Johanson CE (1989) Alteration of sodium transport by the choroid plexus with amiloride. Biochim Biophys Acta Biomembr 979(2):187–192

99.

Katz SE et al (2002) Expression of somatostatin receptors 1 and 2 in human choroid plexus and arachnoid granulations: implications for idiopathic intracranial hypertension. Arch Ophthalmol 120(11):1540–1543PubMed

100.

Panagopoulos GN et al (2007) Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurol Neurophysiol Neurosci:1

101.

Celebisoy N et al (2007) Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 116(5):322–327PubMed

102.

Wenzel RG, Schwarz K, Padiyara RS (2006) Topiramate for migraine prevention. Pharmacotherapy 26(3):375–387PubMed

103.

Diener HC et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27(7):814–823PubMed

104.

Picard F et al (2000) Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 8(9):656–663PubMed

105.

Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7(2):168–181PubMed

106.

Scotton WJ et al (2018) Topiramate is more effective than acetazolamide at lowering intracranial pressure. Cephalalgia 0(0):1–10

107.

Hornby C et al (2018) Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol Publish Ahead of Print

108.

Botfield HF et al (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 9(404):1–11PubMed

109.

Markey KA et al (2016) Idiopathic intracranial hypertension, hormones, and 11beta-hydroxysteroid dehydrogenases. J Pain Res 9:223–232PubMedCentralPubMed

110.

Rauz S et al (2003) Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension. QJM 96(7):481–490PubMed

111.

Sinclair AJ et al (2007) Corticosteroids, 11beta-Hydroxysteroid dehydrogenase Isozymes and the rabbit choroid plexus. J Neuroendocrinol 19(8):614–620PubMed

112.

Markey KA et al (2017) Assessing the efficacy and safety of an 11β-Hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH:DT: clinical methods and Design for a Phase II randomized controlled trial. JMIR Res Protoc 6(9):e181PubMedCentralPubMed

113.

Mollan SP et al (2018) Idiopathic intracranial hypertension: consensus guidelines on management. In: J Neurol Neurosurg psychiatry

114.

Sinclair AJ et al (2010) Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 341:c2701PubMedCentralPubMed

115.

Herd CP et al (2018) Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev 6:Cd011616PubMed

116.

Johnston I, Paterson A (1974) Benign intracranial hypertension. II. CSF pressure and circulation. Brain 97(2):301–312PubMed

117.

Yiangou A et al (2018) Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: minimal gain, is it worth the pain? Cephalalgia 0(0):1–9

118.

Scotton WJ et al (2018) Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open 8(5):e020445PubMedCentralPubMed

119.

Hoffmann J (2018) The utility of the lumbar puncture in idiopathic intracranial hypertension. Cephalalgia 0(0):0333102418787301

120.

Golan S et al (2013) Management and outcome of consecutive pregnancies complicated by idiopathic intracranial hypertension. Isr Med Assoc J 15(4):226–229

121.

Bagga R et al (2005) Choice of therapy and mode of delivery in idiopathic intracranial hypertension during pregnancy. Medscape Gen Med 7(4):42–42

122.

Tang RA et al (2004) Medical and surgical management of idiopathic intracranial hypertension in pregnancy. Curr Neurol Neurosci Rep 5:398–409

123.

Committee on Obstetric Practice, Committee Opinion (2013) Weight gain during pregnancy. Obstet Gynecol 121(1):210–212

124.

Kojima N, Naya M, Makita T (1999) Effects of maternal acetazolamide treatment on body weights and incisor development of the fetal rat. J Vet Med Sci 61(2):143–147PubMed

125.

Holmes LB, Kawanishi H, Munoz A (1988) Acetazolamide: maternal toxicity, pattern of malformations, and litter effect. Teratology 37(4):335–342PubMed

126.

Wilson JG (1971) Use of rhesus monkeys in teratological studies. Fed Proc 30(1):104–109PubMed

127.

Heinonen OP et al (1977) Birth defects and drugs in pregnancy. In: Kaufman DW (ed) Price unstated. American Journal of Medical Genetics. John Wright, Publishing Sciences Group, inc, Littleton, p 516

128.

Weston J et al (2016) Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev (11):CD010224

129.

Huna-Baron R, Kupersmith MJ (2002) Idiopathic intracranial hypertension in pregnancy. J Neurol 249(8):1078–1081PubMed

Title: European Headache Federation guideline on idiopathic intracranial hypertension
Authors: Jan Hoffmann
Susan P Mollan
Koen Paemeleire
Christian Lampl
Rigmor H Jensen
Alexandra J Sinclair
Publication date: 01-12-2018
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-018-0919-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

European Headache Federation guideline on idiopathic intracranial hypertension

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Abnormal brain white matter in patients with right trigeminal neuralgia: a diffusion tensor imaging study

The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

Answer to the comment on Castien et al. (2018) pressure pain thresholds over the cranio-cervical region in headache - a systematic review and meta-analysis